Abstract
Here we report a new chemical inhibitor against HIV-1 with a novel structure and mode of action. The inhibitor, designated as A1836, inhibited HIV-1 replication and virus production with a 50% inhibitory concentration (IC50) of 2.0 μM in an MT-4 cell-based and cytopathic protection antiviral assay, while its 50% cytotoxic concentration (CC50) was much higher than 50 μM. Examination of the effect of A1836 on in vitro HIV-1 reverse transcriptase (RT) and integrase showed that neither were molecular targets of A1836. The characterization and re-infection assay of the HIV-1 virions generated in the presence of A1836 showed that the synthesis of early RT products in the cells infected with the virions was inhibited dose-dependently, due in part to abnormal protein formation within the virions, thus resulting in an impaired infectivity. These results suggest that A1836 might be a novel candidate for the development of a new type of HIV-1 inhibitor.
Original language | English |
---|---|
Pages (from-to) | 121-126 |
Number of pages | 6 |
Journal | BMB Reports |
Volume | 48 |
Issue number | 2 |
DOIs | |
State | Published - 2015 |
Bibliographical note
Publisher Copyright:© 2015 by the The Korean Society for Biochemistry and Molecular Biology.
Keywords
- HIV-1 inhibitor
- Infectivity
- Novel chemical structure
- Reverse transcription
- Viral protein processing